WHO WE ARE

Pro-Pharmaceuticals Inc. is a research leader in developing a new generation of Glyco-upgrade" oncologic drugs. We target sugar-specific binding sites found on cancer cells using carbohydrate technology with the goal of improving efficacy and reducing toxicity of some of the proven, commonly used anti-cancer drugs.

Two platforms of technologies have been identified by Pro-Pharmaceuticals. The first is CARBOSOME" with the lead product DAVANAT-1", which is in Phase I human clinical trials. The second platform is UNIVERSAL CARBOHYDRATE LINKER TECHNOLOGY" (UCLT"), with the lead drug being GALACTOMYCIN" now in pre-clinical development.

For more information, see our Company Timeline and Corporate Fact Sheet.